SOURCE: Nutra Pharma Corp.

May 04, 2006 11:55 ET

Nutra Pharma Sponsors Educational Website for NonTuberculosis Mycobacterium (NTM)

BOYNTON BEACH, FL -- (MARKET WIRE) -- May 4, 2006 --Nutra Pharma Corp. (OTC BB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, has sponsored the website stopNTMnow.com to educate the public about NonTuberculosis Mycobacterium (NTM).

"It is important to educate the public about the importance of NTMs, as they are a leading cause of death in HIV/AIDS and immuno-suppressed patients," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "There are currently over 40 million people suffering from HIV/AIDS that could benefit from this information. For example, most people don't realize that NTMs can be traced to everyday events such as sitting in hot tubs at the community gym."

The stopNTMnow.com website will feature information about NonTuberculosis Mycobacterium: its symptoms, diagnosis and treatments, as well as an interactive communications forum for patients and medical professionals.

"When patients go undiagnosed with NonTuberculosis Mycobacterium, effects can be devastating," commented Neil Roth, President of Designer Diagnostics. "Treatment may require multiple drugs that are known to cause severe side effects. Our ultimate goal is to prevent late stages of the NTM infections from occurring. We believe this can be accomplished by educating the patients about early detection, recognizing the symptoms and showing ways to prevent the infections from spreading."

In March, Designer Diagnostics announced the launch of a medical diagnostics test kit for the rapid isolation and identification of NonTuberculosis Mycobacterium.

About stopNTMnow.com

The occurrence of NTMs is dramatically increasing as the number of HIV/AIDS and other immuno-suppressed patients increase. There are currently more than 40 million people who should be tested for these diseases. stopNTMnow.com is an interactive website designed to educate both patients and medical professionals about NonTuberculosis Mycobacterium (NTM) and ways to prevent late stage infections from developing.

http://www.stopntmnow.com

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.DesignerDiagnostics.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The sponsorship of the stopNTMnow.com should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information